Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
MedImmune Agrees To Purchase Amplimmune
by Rick Mullin
September 2, 2013
| A version of this story appeared in
Volume 91, Issue 35
MedImmune, the biologics division of AstraZeneca, has agreed to acquire Amplimmune for $225 million. The deal will secure for MedImmune several early-stage drug candidates from Amplimmune’s immune-mediated cancer therapy (IMCT) portfolio, including AMP-514, an anti-programmed-cell-death monoclonal antibody in preclinical development. MedImmune’s oncology research is focused on IMCT, in which the immune system is empowered to counteract the tactics used by cancer cells to avoid detection and attack the body. Amplimmune’s owners will be eligible for milestone payments of up to $275 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X